Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Want to cut your energy bills? Here’s how five experts are doing it 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
DUBLIN, Ireland and TREVOSE, Pa., Feb. 27, 2017 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the 37th Annual Cowen and Company Healthcare Conference and the 29th Annual ROTH Conference. The details of the conferences are as follows:
37th Annual Cowen and Company Healthcare Conference
Wednesday, March 8, 2017 at 11:20 am ET
The Boston Marriott Copley Place, Boston, MA
29th Annual ROTH Conference
Monday, March 13 at 12:30 pm PT
The Ritz Carlton, Dana Point, CA
The Company’s presentations will be webcast live and archived on the “Events & Presentations” page in the Investor section of the Company’s website at www.strongbridgebio.com.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations The Trout Group Marcy Nanus +1 646-378-2927 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
